TABLE 1.

Patient demographics, clinical manifestation, type of stent, treatment, and prognosis

Authors, (ref)	Age (years/sex)	Symptoms	Antineoplastic therapy	Time to bleeding (days)	Type of stent	Length of stent (mm)	Diameter of stent (mm)	Bleeding focus	Treatment	Prognosis
Hyun et al. 6	61/M	Melena	Chemotherapy	152	N/A	50–100	10	GDA	TAE	No rebleeding
	51/M	Melena	Chemotherapy	76	N/A	50–100	10	GDA	TAE	No rebleeding
Nezu et al. 7	72/M	Hematemesis and melena	CRT	5	Covered Wallstent	60	10	RHA	None	Died
	82/F	Hematemesis	None	20	Uncovered Wallflex	60	10	PSPDA	TAE	No rebleeding
Fujimori et al. 8	65/F	Hemobilia	Chemotherapy	14	Covered Hanarostent	80	10	GDA	Covered SEMS replacement and TAE	No rebleeding
Our case	74/M	Hematemesis	Chemotherapy	28	D‐ARMS	80	10	GDA	TAE	No rebleeding

Abbreviations: CRT, chemoradiation therapy; D‐ARMS, duckbill‐shaped anti‐reflux metal stent; F, female; GDA, gastroduodenal artery; M, male; N/A, not available; PSPDA, posterior superior pancreaticoduodenal artery; RHA, right hepatic artery; SEMS, self‐expandable metallic stent; TAE, transarterial embolization.